OUR INSIGHTS
Featured Articles
Governing the Gaps
Artificial intelligence does not add a pillar to corporate governance. It tests each of the five the board already holds, and the minutes are the evidence of how the board responded.
The AI-Ready Director: What Health and Life Sciences Boards Now Require
Directors do not need to be technologists. They do need eight competencies, each restated for AI and measured against the oversight duty, when AI becomes central to care, products, and operations.
Improvement or Transformation: How Boards Should Classify AI Proposals
An AI tool that refines a process and one that changes who makes a clinical, coverage, or regulatory decision should not reach the board in the same form. A four-question test helps directors tell them apart.
Orchestrating Oversight
When one committee owns artificial intelligence, the rest of the board stops asking about it. A federated model, written into the charters and coordinated by the chair, closes the gaps.
How Healthcare and Life Sciences Companies Fail: The Sequence a Board Can Interrupt
Insolvency is the last stage of a sequence that starts in the boardroom. Directors who know the four stages, and where AI speeds them, can interrupt the sequence while options are still wide.
The Director's Dilemma
For boards, the question is no longer whether to engage with AI, but how. Four principles draw the series together, and the minutes hold them in place.
What Six Corporate Failures Teach Boards About Overseeing AI
The best-known corporate failures were rarely failures of technology or foresight. They were failures of what the board saw, asked, and recorded, and AI oversight turns on the same question.
Deciding on AI With Imperfect Information
Boards rarely decide with complete information. The failure is using one method for four kinds of gaps. This guide shows directors how to name each gap, match their questions to it, and record what they decided, from R&D programs to AI approvals.
Blind Spots in Healthcare AI: Where Board Oversight Breaks Down
Boards rarely miss AI risk for lack of interest. Here are eight places the board pack does not reach, the evidence behind each, and what directors should ask.